GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Cyclically Adjusted Revenue per Share

Pharma Mar (XMAD:PHM) Cyclically Adjusted Revenue per Share : €11.16 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharma Mar's adjusted revenue per share for the three months ended in Mar. 2024 was €2.168. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €11.16 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Pharma Mar's average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharma Mar was 6.30% per year. The lowest was -0.50% per year. And the median was 3.50% per year.

As of today (2024-05-22), Pharma Mar's current stock price is €36.02. Pharma Mar's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €11.16. Pharma Mar's Cyclically Adjusted PS Ratio of today is 3.23.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 4.32.


Pharma Mar Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Pharma Mar's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Cyclically Adjusted Revenue per Share Chart

Pharma Mar Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.93 9.44 10.17 10.73 11.04

Pharma Mar Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.84 10.95 11.01 11.04 11.16

Competitive Comparison of Pharma Mar's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PS Ratio falls into.



Pharma Mar Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharma Mar's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.168/122.7621*122.7621
=2.168

Current CPI (Mar. 2024) = 122.7621.

Pharma Mar Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.399 101.081 2.914
201409 2.107 100.441 2.575
201412 3.125 100.251 3.827
201503 2.496 99.474 3.080
201506 2.696 101.138 3.272
201509 2.832 99.559 3.492
201512 2.507 100.268 3.069
201603 2.287 98.638 2.846
201606 2.709 100.333 3.315
201609 2.575 99.737 3.169
201612 2.244 101.842 2.705
201703 2.469 100.896 3.004
201706 2.794 101.848 3.368
201709 1.464 101.524 1.770
201712 1.897 102.975 2.262
201803 1.510 102.122 1.815
201806 2.093 104.165 2.467
201809 1.214 103.818 1.436
201812 1.084 104.193 1.277
201903 1.053 103.488 1.249
201906 1.191 104.612 1.398
201909 1.142 103.905 1.349
201912 1.262 105.015 1.475
202003 5.380 103.469 6.383
202006 3.791 104.254 4.464
202009 2.922 103.521 3.465
202012 2.639 104.456 3.101
202103 2.824 104.857 3.306
202106 2.613 107.102 2.995
202109 2.312 107.669 2.636
202112 4.969 111.298 5.481
202203 2.953 115.153 3.148
202206 2.667 118.044 2.774
202209 2.437 117.221 2.552
202212 2.806 117.650 2.928
202303 1.891 118.948 1.952
202306 2.571 120.278 2.624
202309 2.105 121.343 2.130
202312 2.296 121.300 2.324
202403 2.168 122.762 2.168

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Pharma Mar  (XMAD:PHM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharma Mar's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.02/11.16
=3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 4.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharma Mar Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar (XMAD:PHM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Pharma Mar (XMAD:PHM) Headlines

From GuruFocus

Q1 2019 PulteGroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2020 PulteGroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2020 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024